No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BLUE bluebird bio
- 0.923
- -0.048-4.91%
Close Apr 24 16:00 ET
177.88MMarket Cap-1464P/E (TTM)
1.020High0.913Low8.18MVolume0.990Open0.971Pre Close7.65MTurnover4.27%Turnover RatioLossP/E (Static)192.74MShares5.53052wk High0.80P/B177.05MFloat Cap0.87952wk Low--Dividend TTM191.84MShs Float152.883Historical High--Div YieldTTM11.07%Amplitude0.879Historical Low0.935Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Cerebral Adrenoleukodystrophy Pipeline Insight 2024, Featuring Key Players Minoryx Therapeutics, POXEL, Orpheris and Bluebird Bio
Bluebird Bio Inc Anticipates It Will Be Delayed In Filing Its Quarterly Report On Form 10-Q For Q1 Of 2024
Bluebird Bio Inc Anticipates It Will Be Delayed In Filing Its Quarterly Report On Form 10-Q For Q1 Of 2024
TD Cowen Says Sickle Cell Therapies May Get Higher CMS Payments
Is Bluebird Bio Stock a Buy?
Better Buy: Bluebird Bio Vs. Novavax
Is This Beaten-Down Stock a Good Acquisition Target?
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
